Several brokerages have updated their recommendations and price targets on shares of Alexion Pharmaceuticals (NASDAQ: ALXN) in the last few weeks:
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) traded down 0.08% on Friday, reaching $118.83. The company had a trading volume of 472,345 shares. The company has a market capitalization of $26.64 billion, a P/E ratio of 72.46 and a beta of 1.45. The stock’s 50-day moving average is $122.91 and its 200-day moving average is $129.23. Alexion Pharmaceuticals Inc. has a 52 week low of $110.56 and a 52 week high of $193.45.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.04 by $0.19. The firm earned $799 million during the quarter, compared to analyst estimates of $787.07 million. Alexion Pharmaceuticals had a return on equity of 10.58% and a net margin of 12.46%. Alexion Pharmaceuticals’s quarterly revenue was up 19.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.16 earnings per share. Equities research analysts forecast that Alexion Pharmaceuticals Inc. will post $4.64 EPS for the current fiscal year.